Outline of Hiroshima Cancer Seminar Public Interest Incorporated Foundation
As is well known, Hiroshima was the first city in the world to be struck with an atomic bomb, and the relative risk for hematological malignancies and solid cancers is high among atomic bomb survivors. Our goal now is to promote everlasting peace and the abolition of nuclear weapons. However, there are still many people suffering and dying from cancer in Hiroshima.
As a step towards the noble goal of the conquest of cancer, the Hiroshima Cancer Seminar Foundation was established in 1992 with the cooperation of Hiroshima Prefectural Government, Hiroshima University, Hiroshima Financial Circles and Hiroshima Medical Association and then was authorized as the Public Interest Incorporated Foundation on the first day of April 2013.
The Foundation annually holds an international symposium to create an opportunity for basic scientists and clinical researchers to exchange ideas on cancer research and cancer therapy.
Eiichi Tahara (Professor emeritus, Hiroshima University), Chairman of the Foundation, every year serves as chairman of the Organizing Committee for the symposia, and has published the meeting reports of the symposia in Cancer Science and JJCO journals. The subjects of previous symposia and the invited speakers were as below.
Another important task of the Foundation is a lecture open to the public to distribute precise information on cancer prevention, diagnosis and treatment of human cancer. The Foundation annually reports Hiroshima Cancer Seminar (HCS) News including the summary of the open lectures, symposia and budgets as well as other activities.
In addition, the first meeting on the Advanced Cancer Drug Therapy (ACDT) was organized on 9th February 2013 to promote cancer drug therapy for the aged cancer patients and encourage the development of cancer professionals. This ACDT meeting will be annually held as well.
The Foundation also supports the activity of young cancer researchers and oncologists as well as scientific cancer related societies.
The Hiroshima Cancer Seminar Public Interest Incorporated Foundation hopes to promote and support further advances in controlling cancer, from the basic research to clinical oncology.
The group photo of the 22nd HCS/the 4th JARI Joint International Symposium
“MicroRNAs in Cancer”.
| Date | Main theme | Invited speakers | |
| 1st | November 10, 1990 | New approach to cancer therapy | T.Sugimura, S.Waxman, M.Hozumi, L.Degos, R.Lotan, Y.S.Cho-Chung, K.Hashimoto, N.Shimizu, M.Yamakido, G.B.Pierce, Y.Nakamura, D.Tarin |
| 2nd | June 6-7, 1992 | Carcinogenesis and metastasis | T.Sugimura, C.C.Harris, A.P.Grollman, J.E.Trosko, S.Nishimura, I.J.Fidler, S.Tsukita, S.Taniguchi, O.Niwa, H.Yokozaki, N.Tanigawa, K.Kurisu, M.Oshimura |
| 3rd | October 23-24, 1993 | Tumor suppressor gene | E.J.Stanbridge, J.Yokota, M.Oshimura, E.Harlow, Y.Nakamura, D.Tarin, T.Takahashi, T.Seyama, A.Ochiai, W.Yasui |
| 4th *1 |
October 22-26, 1994 | Gene therapy of cancer | T.Sugimura, A.B.Deisseroth, M.Blease, M.L.Kripke, I.Pastan, J.Yoshida, H.Hamada, D.R.J.Macer,Y.Niitsu, M.Terada |
| 5th | October 28-29, 1995 | Telomerase and cancer | C.B.Harley, T.de Lange, M.Oshimura, J.W.Shay, H.Tahara, K.Hiyama, E.Hiyama, J.H.Ohyashiki, F.Ishikawa |
| 6th *2 |
October 22-24, 1996 | Cancer-stromalinteraction | R.R.Brentani, R.Lotan, M.Ogawa, I.P.Witz, Y.Okada, T.Kuroki, D.Tarin, M.Terada |
| 7th | November 15-16, 1997 | Gene therapy: application to disease | I.M.Verma, F.Wong-Staal, W.K.Cavenee, J.C.Barrett, Y.Kawakami, Y.Sugimoto |
| 8th | November 2-3, 1998 | Aging and cancer | J.C.Barrett, M.Oshimura, T.E.Johnson, M.Kuroo, F.Ishikawa, Z.Ronai |
| 9th | September 28, 1999 | Pediatric Tumors and Secondary Cancer | Anna T.Meadows, Ed Harlow, Peter Inskip, Masao Seto, Yukiko Tsunematsu, Nanao Kamada |
| 10th | October 28-29, 2000 | Gene diagnosis – Introduction of new technology – |
J. Quachenbush, T. Tsunoda, M. Nishiyama, N. Shimizu, H. Shimada, H. Yokozaki, Y. Shirai |
| 11th | October 27, 2001 | Chromatin and Cancer | R. Grosschedl, P.A. Jones, T. Kouzarides, K. Igarashi, T. Ito, M. Oshimura, M. Kanno |
| 12th | November 9, 2002 | Molecular targeting therapy for cancer | W. K. Cavenee, F. B. Furnari, R. Fishel, T. Tsuruo, K. Nishio, S. Yano, S. Sone, M. Toi |
| 13th | October 26, 2003 | New approaches to identification of biomarkers for early cancer detection | C. C. Harris, X. W. Wang, S. M. Hewitt, M. Toyota, K. Imai, K. Shimizu, S. Hirohashi, N. Takahashi, W. Yasui |
| 14th | October 30-31, 2004 | Cancer and epigenetics -Basic research and clinical implication- | J.P. Issa, M. Oshimura, S. Fujii, Y. Kondo, A.P. Feinberg, M. Nakao, I. Kitabayashi, T. Ushijima, V.V. Lobanenkov, H. Tahara, E. Verdin, M. Yoshida |
| 15th | October 30, 2005 | Current Progress of Cancer Chemotherapy | J.A. Ajani, A. Ohtsu, C.H. Kohne, M. Monden, R.S. Kerbel, M. Fukuoka, R. B. Diasio, T. Saeki, M. Nishiyama, K. Yoshida, M. Tahara |
| 16th | October 22, 2006 | Cancer Stem Cells | E. Quintana, F. Radtke, K. S. Kang, L. Mishra, Y. Ito, S. Nishikawa, A. Hirao, T. Kondo, M. Mori, H. Taniguchi |
| 17th *3 |
November 11, 2007 | Radiation Therapy for Cancer | J.D. Cox, T. Ogino, B. Vikram, H.Shirato, Y. Hirokawa, T. Akimitsu, R.U. Komaki-Cox, S. Yamada, S-J, Huh, M. Hiraoka, S.M.Bentzen |
| 18th *4 |
November 9, 2008 | Recent Progress in Pathogenesis and Management of Colorectal Cancer | N.A. Wright, M. Taketo, R.N. DuBois, W. Yasui, S.Tanaka, Y.Niitsu, Y. Matsumura, K. Sugihara, M. Okajima, M. Ikeguchi, K. Takenaga |
| 19th *5 |
November 1, 2009 | Recent Progress in Carcinogenesis, Progression and Therapy of Lung Cancer | C. C. Harris, T. Takahashi, D. G. Beer, M. Kato, K. Inai, Y. Daigo, T. Mitsudomi, I. Okamoto, E. Shimizu, T. Isobe |
| 20th *6 |
October 31, 2010 | Recent Progress in Carcinogenesis, Progression and Therapy of Breast Cancer | T. D. Tlsty, E. T. Liu, H. Tahara, M.D.Pegram, T. Ochiya, M. Toi, S. Yamamoto, Y. Fujiwara, M. Ohara, M. Itakura, K. Ishiguro |
| 21st *7 |
November 6, 2011 | Recent Progress in Carcinogenesis, Progression and Management of Upper GI Cancers | R. Peek Jr, M. Hatakeyama, T. Ushijima, W. Yasui, A. Ochiai, H. Yokozaki, J. Nakayama, J. Sung, Y. Kitadai, A. Ohtsu, I. Uyama, T. Matsubara, H. Saito |
| 22nd *8 |
August 30, 2012 | MicroRNAs in Cancer | M A. Kay, H. Suzuki, J. Inazawa, H. Tahara, A L. Kasinski, N. Seki, N. Oue, N. Kosaka |
| 23rd *9 |
Agust 29-31, 2013 | Liquid biopsy promises for RNAi medicine |
A F Hill, Y S Gho, H Suzuki, N Kosaka, H Tahara, K Suzuki, |
|
24th |
Agust 26-28, 2015 | All about EVs-Liquid biopsy |
M Wauben,H Siku,Y Kawakami Y Takakura,H Tamura,H Ishii,Y Yamada,Y Tomari |
| 25th *11 |
Agust 31-September 2, 2016 | Toward deep RNA sciences for clinical applications |
T-L Shen,T Umezu,A Kotani, T Mitaaka,T Wada, S Komatsu, |
| 26th *12 |
Agust 30-September 1, 2017 | New frontiers of exosome research in the Asia-Pacific |
Y Baba,A Nakano,Y. S. Gho,H H Yin,S-K Lim,A Hill,A Yokoi, |
*1 in conjunction with the 8th International Conference of the International Society of Differentiation.
*2 in conjunction with the 1st International Conference on Gastroenterological Carcinogenesis.
*3 in conjunction with the 1st Three Universities’ Consortium (The Cancer Professional Training Plan. Tottori University, Shimane University and Hiroshima University)
The 15th Anniversary of Hiroshima Cancer Seminar Foundation
*4 in conjunction with the 2nd Three Universities’ Consortium (The Cancer Professional Training Plan. Tottori University, Shimane University and Hiroshima University)
*5 in conjunction with the 3rd Three Universities’ Consortium (The Cancer Professional Training Plan. Tottori University, Shimane University and Hiroshima University)
*6 in conjunction with the 4th Three Universities’ Consortium (The Cancer Professional Training Plan. Tottori University, Shimane University and Hiroshima University)
*7 in conjunction with the 5th Three Universities’ Consortium (The Cancer Professional Training Plan. Tottori University, Shimane University and Hiroshima University)
*8 in conjunction with the 4th JARiJoint International Symposium
*9 in conjunction with the 5th JARiJoint International Symposium
*10 in conjunction with the 6th JARi･2thJSVE Joint International Symposium
*11 in conjunction with the 7th JARi･3thJSVE Joint International Symposium
*12 in conjunction with the 8th JARi･4thJSVE Joint International Symposium
Eiichi Tahara, MD. PhD.（Hon）, FRCPath
Date and Place of Birth:
July 19,1936, Yokohama, Japan
Present Position:
Professor emeritus, Hiroshima University
Chairman of the Hiroshima Cancer Seminar Foundation
Education:
MD, Hiroshima University School of Medicine, 1963; PhD,1968
Brief Chronology of Employment:
Professor and Chairman at the Department of Pathology, Hiroshima University, 1978-2000;
Councilor of Hiroshima University, 1985-1987;
Director, Faculty of Medicine, Hiroshima University School of Medicine1996-1998;
Chairman of the Hiroshima Cancer Seminar Foundation, 1999;
Professor emeritus, Hiroshima University 2000;
Visiting Professor UCSD Cancer Center 2001;
Permanent Director and Chief of Research, Radiation Effect Research Foundation (RERF), 2001-2005;
Senior Consultant Researcher, RERF, 2005-2006;
Member of the Senior Review Panel on Future Planning of RERF, 2006-present.
Specialty and Present Interest:
Molecular pathology and gene diagnosis of gastroenterological cancer.
Professional Affiliations:
The International Society of Differentiation, President, 1996-98;
The International Society of Gastroenterological Carcinogenesis, Founder, Secretary general, 1996-;
The Pathological Society of Great Britain and Ireland, honorary membership, 1998;
The Japanese Cancer Association, President, 1999, honorary member 2004:
The Japanese Society of Pathology, President, 1998, honorary member 2000;
AACR Emeritus member President’s Circle Leadership Council, Emeritus member 2014, AACR Foundation, 2005-;
The International Cancer Microenvironment Society (ICMS), charter member and officer, 2007.
Honors and Awards:
The Hiroshima Medical Association Award, 1972;
Litchfield Lectureship. University of Oxford, 1991,1995;
R.E. “Bob” Smith Lecture Award, University of Texas, MD Anderson Cancer Center 1997;
Honorary Fellowship of the Royal College of Pathologists, UK.1998;
Invited participant, First Summit of Leaders of World Cancer Research Organization, 1999;
Signature of the “Charter of Paris”, World Summit against Cancer, 2000;
Corresponding Member Award ,Germany Society of Pathology, 2000;
“Nagayo” Prize, Japanese Cancer Association, 2002;
Japan Cancer Society Prize (organization), 2010.
Japanese Society of Gastroenterological Carcinogenesis(JSGC) founded Eiichi Tahara Prize, 2013
A total of 1211 manuscripts including 175 books (English 53) and 1036 originals and reviews (English 487).